Russell Weiner’s Post

Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology

Unlock the secrets of hematology staining techniques with our latest blog post on the Wright-Giemsa stain! Perfect for laboratory professionals and students, this guide provides step-by-step instructions to help you achieve precise and accurate results 🔬🎨 Dive into the details here: https://bit.ly/3ycvOvL #WrightGiemsa #LabTutorial #HardyDiagnostics

HaemaLogiX Ltd Chief Scientific Officer Dr Rosanne Dunn explains the key highlights of the abstract that was recently published in the European Hematology Association (EHA)’s official open access journal, HemaSphere Journal. Dr Dunn highlights that the data have shown that 100% of amyloidosis patient bone marrow plasma cells express either LMA or KMA. It is also highlighted that LMA and KMA define treatment-resistant, disease-causing plasma cells – in keeping with our published KappaMab Phase 2b clinical results which have also shown that our immunotherapies can deplete these persistent aberrant cells without affecting normal immune cells. Watch the full video below from Dr Dunn on the key highlights of this published data. For more details on this pre-clinical data and its publication, visit our website via this link: https://bit.ly/4b1QgNg

Should be an informative webinar for patient and doctor alike who are invested in the latest research from ASH 2023 on CLL/SLL

We are excited to provide updated clinical safety and efficacy data from 18 sickle cell disease patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2/3 RUBY clinical trial at European Hematology Association (EHA) annual congress. Treated patients show early normalization of total hemoglobin with a mean within the normal range at >14 g/dL, as well as rapid and sustained improvements in fetal hemoglobin and percentage of F-cells of >40 and >90%, respectively. Additionally, all treated patients have been free of vaso-occlusive events for up to 22.8 months of follow-up. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology #SickleCellDisease

How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology

🌟 Publication Alert! 🌟   We are thrilled to share a recent peer-reviewed study published in the International Journal of Laboratory Hematology, titled “Metrological traceability in flow cytometry? Evaluation of a new volumetric method for lymphocyte subsets”.   🔍 𝗠𝗲𝘁𝗵𝗼𝗱: The study compares the traditional bead-based technique with the volumetric method on the Sysmex XF-1600 flow cytometer for lymphocyte subset enumeration using the Sysmex KOMBITEST TBNK 6-color test system.   📊 𝗢𝘂𝘁𝗰𝗼𝗺𝗲: The results indicate a high degree of correlation between both methodologies, with biases within clinically acceptable limits.   📌 𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻: The study highlights the importance of precise lymphocyte enumeration and the value of innovative technologies in clinical practice. This research underscores the robustness and clinical reliability of metrologically traceable lymphocyte subset counts produced by XF-1600 flow cytometer using the Sysmex KOMBITEST TBNK 6-color test system.   📖 Read the full article here: https://lnkd.in/er9X-jKQ   #FlowCytometry #ClinicalResearch #Sysmex